1887

Abstract

Conventional culture and drug susceptibility testing (DST) methods for are laborious and time consuming. For this reason alternative rapid culture and DST techniques are urgently needed to shorten the time for drug-resistance detection. A total of 222 smear-positive sputum samples were evaluated by the direct nitrate reductase assay (D-NRA) on Lowenstein–Jensen medium, for the rapid and simultaneous detection of resistance to isoniazid, rifampicin, kanamycin and ofloxacin. -Nitrobenzoic acid was also included for identification of the complex. Results were compared with the BACTEC MGIT 960 as gold standard. The general performance of the D-NRA was very good, reaching a global value of 97 %. D-NRA had a turn-around time of 16.9 days to obtain results while that of the indirect MGIT 960 system was 29 days. D-NRA is a low-cost technology, easy to set up in clinical laboratories and suitable to be used for DST of in all smear-positive samples.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.070219-0
2014-04-01
2019-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/4/522.html?itemId=/content/journal/jmm/10.1099/jmm.0.070219-0&mimeType=html&fmt=ahah

References

  1. Affolabi D., Odoun M., Martin A., Palomino J. C., Anagonou S., Portaels F.. ( 2007;). Evaluation of direct detection of Mycobacterium tuberculosis rifampin resistance by a nitrate reductase assay applied to sputum samples in Cotonou, Benin. . J Clin Microbiol 45:, 2123–2125. [CrossRef][PubMed]
    [Google Scholar]
  2. Angeby K. A., Klintz L., Hoffner S. E.. ( 2002;). Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. . J Clin Microbiol 40:, 553–555. [CrossRef][PubMed]
    [Google Scholar]
  3. Becton Dickinson and Company ( 2005;). BD BACTEC MGIT 960 SIRE kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. . http://www.bd.com/ds/technicalCenter/clsi/clsi-960sire.pdf
  4. Coban A. Y., Birinci A., Ekinci B., Durupinar B.. ( 2004;). Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay. . Int J Antimicrob Agents 24:, 304–306. [CrossRef][PubMed]
    [Google Scholar]
  5. Heifets L. B.. ( 1991;). Drug susceptibility test in the management of chemotherapy of tuberculosis. . In Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, pp. 89–121. Edited by Heifets L. B... Boca Raton:: CRC Press;.
    [Google Scholar]
  6. Imperiale B. R., Cataldi A. A., Morcillo N. S.. ( 2011;). Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specific polymerase chain reaction. . Int J Tuberc Lung Dis 15:, 496–501. [CrossRef][PubMed]
    [Google Scholar]
  7. Imperiale B. R., Zumárraga M. J., Weltman G., Zudiker R., Cataldi A. A., Morcillo N. S.. ( 2012;). First evaluation in Argentina of the GenoType® MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from clinical isolates and specimens. . Rev Argent Microbiol 44:, 283–289.[PubMed]
    [Google Scholar]
  8. Imperiale B. R., Zumárraga M. J., Di Giulio A. B., Cataldi A. A., Morcillo N. S.. ( 2013;). Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. . Int J Tuberc Lung Dis 17:, 1088–1093. [CrossRef][PubMed]
    [Google Scholar]
  9. Martin A., Panaiotov S., Portaels F., Hoffner S., Palomino J. C., Angeby K.. ( 2008;). The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. . J Antimicrob Chemother 62:, 56–64. [CrossRef][PubMed]
    [Google Scholar]
  10. Martin A., Imperiale B., Ravolonandriana P., Yilmaz Coban A., Akgunes A., Ikram A., Satti L., Odoun M., Pandey P.. & other authors ( 2014;). Prospective multicentre evaluation of the direct nitrate reductase assay for the rapid detection of extensively drug-resistant tuberculosis. . J Antimicrob Chemother 69:, 441–444. [CrossRef][PubMed]
    [Google Scholar]
  11. Ministry of Health ( 2011;) Tuberculosis situation in Argentina. Epidemiological Bulletin. http://msal.gov.ar/htm/site/sala_situacion/PANELES/BEP46-web/BEP46_TBC_int.pdf
    [Google Scholar]
  12. Morcillo N., Imperiale B., Palomino J. C.. ( 2008;). New simple decontamination method improves microscopic detection and culture of mycobacteria in clinical practice. . Infect Drug Resist 1:, 21–26. [CrossRef][PubMed]
    [Google Scholar]
  13. Morcillo N., Imperiale B., Di Giulio B.. ( 2010;). Evaluation of MGIT 960 and the colorimetric-based method for tuberculosis drug susceptibility testing. . Int J Tuberc Lung Dis 14:, 1169–1175.[PubMed]
    [Google Scholar]
  14. Musa H. R., Ambroggi M., Souto A., Angeby K. A.. ( 2005;). Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples. . J Clin Microbiol 43:, 3159–3161. [CrossRef][PubMed]
    [Google Scholar]
  15. National Institute of Infectious Diseases ( 2010;) XL Annual meeting of the Confederal Council of Tuberculosis, Dr Carlos Malbrán, Buenos Aires, Argentina, November 24–25 2010.
    [Google Scholar]
  16. Richter E., Rüsch-Gerdes S., Hillemann D.. ( 2006;). Evaluation of the GenoType Mycobacterium Assay for identification of mycobacterial species from cultures. . J Clin Microbiol 44:, 1769–1775. [CrossRef][PubMed]
    [Google Scholar]
  17. Rüsch-Gerdes S., Pfyffer G. E., Casal M., Chadwick M., Siddiqi S.. ( 2006;). Multicenter laboratory validation of susceptibility testing of the BACTEC MGIT 960 technology for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. . J Clin Microbiol 44:, 688–692. [CrossRef][PubMed]
    [Google Scholar]
  18. Sharma B., Pal N., Malhotra B., Vyas L.. ( 2010;). Evaluation of a rapid differentiation test for Mycobacterium tuberculosis from other Mycobacteria by selective inhibition with p-nitrobenzoic acid using MGIT 960. . J Lab Physicians 2:, 89–92. [CrossRef][PubMed]
    [Google Scholar]
  19. Tuberculosis Control Program of Buenos Aires Province ( 2012;) Epidemiological report, year 2010. Ministry of Health, La Plata, August 2012.
    [Google Scholar]
  20. WHO ( 2008;). Anti-tuberculosis Drug Resistance in the World. Fourth Global Report. WHO/HTM/TB/2008.394. http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf
    [Google Scholar]
  21. WHO ( 2009;). Global Tuberculosis Control. Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411. http://whqlibdoc.who.int/publications/2009/9789241563802_eng_doc.pdf
    [Google Scholar]
  22. WHO ( 2010;). Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 354 2010 Global Report on Surveillance and Response. 355 WHO/HTM/TB/2010.3. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf?ua=1
    [Google Scholar]
  23. WHO ( 2011;) Noncommercial Culture and Drug-Susceptibility Testing Methods for Screening Patients at Risk for Multidrug-Resistant Tuberculosis (2011). Policy Statement. http://www.who.int/tb/publications/2011/mdr_tb_diagnostics_9789241501620/en/
    [Google Scholar]
  24. WHO ( 2012;). Global Tuberculosis Report. WHO/HTM/TB/2012.6. http://www.who.int/tb/publications/global_report/gtbr12_main.pdf
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.070219-0
Loading
/content/journal/jmm/10.1099/jmm.0.070219-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error